Kera Capital Partners Inc. Purchases Shares of 25,770 Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)

Kera Capital Partners Inc. bought a new stake in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) during the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 25,770 shares of the company’s stock, valued at approximately $106,000.

Other hedge funds have also recently made changes to their positions in the company. Nantahala Capital Management LLC bought a new stake in Eledon Pharmaceuticals in the 2nd quarter valued at $1,584,000. Geode Capital Management LLC lifted its stake in Eledon Pharmaceuticals by 9.7% in the third quarter. Geode Capital Management LLC now owns 378,058 shares of the company’s stock worth $942,000 after purchasing an additional 33,569 shares during the last quarter. Armistice Capital LLC boosted its holdings in Eledon Pharmaceuticals by 1.7% during the 2nd quarter. Armistice Capital LLC now owns 2,336,000 shares of the company’s stock valued at $6,167,000 after acquiring an additional 39,000 shares during the period. Dimensional Fund Advisors LP bought a new stake in Eledon Pharmaceuticals during the 2nd quarter valued at about $80,000. Finally, Clarity Capital Partners LLC bought a new position in Eledon Pharmaceuticals in the third quarter worth approximately $29,000. Institutional investors own 56.77% of the company’s stock.

Eledon Pharmaceuticals Stock Down 0.2 %

Shares of ELDN stock opened at $4.02 on Monday. The firm has a market cap of $240.15 million, a price-to-earnings ratio of -2.00 and a beta of 0.79. Eledon Pharmaceuticals, Inc. has a 52-week low of $1.52 and a 52-week high of $5.54. The company’s 50 day moving average is $4.31 and its 200 day moving average is $3.41.

Eledon Pharmaceuticals (NASDAQ:ELDN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). Analysts anticipate that Eledon Pharmaceuticals, Inc. will post -0.63 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Eledon Pharmaceuticals in a research note on Wednesday, November 20th.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).